ISAB: Revenue fell sharply, but cost cuts and new funding support a push toward profitability

About this update from Inhalation Sciences Sweden Ab

Revenue and order intake declined year-over-year, but cost reductions and a successful rights issue have strengthened liquidity. FDA validation and new commercial partnerships support growth initiatives, with a focus on converting a robust offer pipeline into sales.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Inhalation Sciences Sweden Ab